Select Publications

Publications discussed by Dr Miller

Gennari A et al. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer. Clin Breast Cancer 2002;3(5):346-52. Abstract

O’Shaughnessy, J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract

Perez EA et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001;19(22):4216-23. Abstract

Sledge GW et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An Intergroup trial (E1193). J Clin Oncol 2003;21(4):588-92. Abstract

Stemmler HJ et al. Weekly docetaxel (Taxotere) in patients with metastatic breast cancer. Ann Oncol 2001;12(10):1393-8. Abstract

Estrogen receptor downregulator, fulvestrant

Bundred NJ et al. Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen. Anticancer Res 2002;22(4):2317-9. Abstract

Bundred N, Howell A. Fulvestrant (Faslodex): Current status in the therapy of breast cancer. Expert Rev Anticancer Ther 2002;2(2):151-60. Abstract

Carlson RW. Sequencing of endocrine therapies in breast cancer--integration of recent data. Breast Cancer Res Treat 2002;75 Suppl 1:S27-32;discussion S33-5. Abstract

Cheung KL, Robertson JF. Fulvestrant. Expert Opin Investig Drugs 2002;11(2):303-308. Abstract

Costantino J. The impact of hormonal treatments on quality of life of patients with metastatic breast cancer. Clin Ther 2002;24 Suppl C:C26-42. Abstract

Cummings FJ. Evolving uses of hormonal agents for breast cancer therapy. Clin Ther 2002;24 Suppl C:C3-25. Abstract

Curran M, Wiseman L. Fulvestrant. Drugs 2001;61(6):807-13;discussion 814. Abstract

Dowsett M et al. Effect of HER2 amplification status on the antiproliferative response of ER+ primary breast cancer to fulvestrant (Faslodex). Breast Cancer Res Treat 2002; Abstract 365.

Elkak AE, Mokbel K. Pure antiestrogens and breast cancer. Curr Med Res Opin 2001;17(4):282-9. Abstract

Howell A et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20(16):3396-403. Abstract

Howell A. Future use of selective estrogen receptor modulators and aromatase inhibitors. Clin Cancer Res 2001;7(12 Suppl):4402s-4410s;discussion 4411s-4412s. Abstract

Howell A. Postmenopausal women with advanced breast cancer who progress on fulvestrant or tamoxifen retain sensitivity to further endocrine therapies. Breast Cancer Res Treat 2002; Abstract 251.

Howell A. Preliminary experience with pure antiestrogens. Clin Cancer Res 2001;7(12 Suppl):4369s- 4375s;discussion 4411s-4412s. Abstract

Johnston SR. Endocrine manipulation in advanced breast cancer: Recent advances with SERM therapies. Clin Cancer Res 2001;7(12 Suppl):4376s-4387s;discussion 4411s-4412s. Abstract

Jones SE. A new estrogen receptor antagonist--An overview of available data. Breast Cancer Res Treat. 2002;75 Suppl 1:S19-21;discussion S33-5. Abstract

Massarweh S et al. The estrogen receptor antagonist fulvestrant, but not the partial antagonist tamoxifen, is an effective endocrine treatment in a xenograft model of HER2 overexpressing breast cancer. Breast Cancer Res Treat 2002; Abstract 247.

Morris C, Wakeling A. Fulvestrant ('Faslodex')—A new treatment option for patients progressing on prior endocrine therapy. Endocr Relat Cancer 2002;9(4):267-76. Abstract

Osborne CK et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002;20(16):3386-95. Abstract

Parker LM et al. Greater duration of response in patients receiving fulvestrant ('Faslodex') compared with those receiving anastrozole ('Arimidex'). Proc ASCO 2002; Abstract 160.

Parker LM. Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer. Clin Ther 2002;24 Suppl C:C43-57. Abstract

Perey L et al. Fulvestrant (‘Faslodex’) as a hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and non-steroidal aromatase inhibitors: An ongoing phase II SAKK trial. San Antonio Breast Cancer Symposium 2002:Poster 249.

Pritchard KI. Endocrine therapy of advanced disease: Analysis and implications of the existing data. Clin Cancer Res 2003;9(1 Pt 2):460S-7S. Abstract

Robertson JF. Estrogen receptor downregulators: New antihormonal therapy for advanced breast cancer. Clin Ther 2002;24 Suppl A:A17-30. Abstract

Robertson JF. ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data. Br J Cancer 2001;85 Suppl 2:11-4. Abstract

Wardley AM. Fulvestrant: A review of its development, pre-clinical and clinical data. Int J Clin Pract 2002;56(4):305-9. Abstract

Home · Search